Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

about

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

P2860

Q26771331-CA040446-7146-40AD-88F6-8F49E0F5DA0B

P2860

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

Item

http://www.wikidata.org/entity/Q42588915

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@en

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@nl

type

Item

label

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@en

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@nl

prefLabel

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@en

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@nl

P1476

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

@en

P2093

Benedetto Bruno

http://www.w3.org/2001/XMLSchema#string

Luisa Giaccone

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

Moreno Festuccia

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

Allogeneic hematopoietic cell transplantation for multiple myeloma.

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.

P304

e2010013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4084/MJHID.2010.013

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21415966

http://www.w3.org/2001/XMLSchema#string

P932

3033139

http://www.w3.org/2001/XMLSchema#string

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

about

P2860

P2860

Role of allogeneic transplantation in multiple myeloma in the era of new drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932